Aura Biosciences (AURA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Ocular Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 49/100 (MEDIUM), 8.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 11.1% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Aura Biosciences to Participate in Upcoming Investor Conference
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
- Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
- Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
- Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Aura Biosciences.
Full AURA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.